T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors

MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic,

The Next Chapter of B7-H3: From Systemic Disease to the Brain

Early Data for T-MAXIMUM's B7-H3 Allogeneic CAR-T in Brain Metastases Presented at WCLC 2026 BEIJING, Sept.

The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?

T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung

Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102

Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI